Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme

Piazza, Marcello; Safary, Assad; Vegnente, Angela; Soncini, Renato; Pensati, Pasqualina; Sardo, Massimo; Orlando, Raffaele; Tosone, Grazia; Picciotto, L

doi:10.1016/s0264-410x(98)00237-0

Cited by 64 publications

(25 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Passively-transferred maternal antibody can reduce or abolish the response of very young infants to HAV vaccination [66,67]. An Israeli study in 300 infants found that there was a marked response if, in addition to vaccination at 2, 4 and 6 months, a further vaccination was given at 12 months of age [68].…”

Section: André Van Damme Safary and Banatvalamentioning

confidence: 99%

Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use

André

Damme

Safary

et al. 2002

Expert Review of Vaccines

Self Cite

View full text Add to dashboard Cite

There is 10 years of marketing experience with the hepatitis A vaccine Havrix. It is highly immunogenic, provides lasting protection in healthy individuals and generates protective levels of antibodies in patients with chronic liver disease or impaired immunity. Postmarketing surveillance data have confirmed the outstanding safety profile of the vaccine. The timing of the booster dose is not critical to effectiveness, which has advantages for the protection of travelers to regions of high endemicity. The vaccine is effective in curbing outbreaks of hepatitis A and also when administered postexposure, due to rapid seroconversion and the long incubation period of the disease. In intermediate endemic regions, an epidemiological shift in hepatitis A infection has driven the development of universal preventive strategies to be added to the targeting of at-risk groups. Existing official recommendations and future directions for vaccine use are reviewed.

show abstract

Section: André Van Damme Safary and Banatvalamentioning

confidence: 99%

Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use

André

Damme

Safary

et al. 2002

Expert Review of Vaccines

Self Cite

View full text Add to dashboard Cite

show abstract

“…14,15 Limited data indicate that the presence of anti-HAV interferes with the immune response to hepatitis A vaccine in infants and young children. [16][17][18] To evaluate the effect of maternal antibody on vaccine response in infants, we conducted a clinical trial to determine the immunogenicity of hepatitis A vaccine administered to infants beginning at 2 months of age along with other routinely administered vaccines.…”

mentioning

confidence: 99%

Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants

Letson¹,

Shapiro²,

Kuehn³

et al. 2004

The Journal of Pediatrics

View full text Add to dashboard Cite

“…dose of HAVRIX R in a group of 48 infants immunized at 5 and 11 months of age [41]. dose of HAVRIX R in a group of 48 infants immunized at 5 and 11 months of age [41].…”

Section: Immunogenicitymentioning

confidence: 99%

Hepatitis A Vaccination in Infants: The Ultimate Solution to A Long-Standing Public Health Problem

Letson¹,

Margolis²

2007

CPR

View full text Add to dashboard Cite

show abstract

Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme

Cited by 64 publications

References 9 publications

Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use

Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use

Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants

Hepatitis A Vaccination in Infants: The Ultimate Solution to A Long-Standing Public Health Problem

Contact Info

Product

Resources

About